LOGIN  |  REGISTER
C4 Therapeutics
Astria Therapeutics

Owens & Minor to Present at Upcoming Investor Conferences

December 02, 2024 | Last Trade: US$3.15 0.04 1.29

RICHMOND, Va. / Dec 02, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), announced today that members of its management team are scheduled to participate in two upcoming investor conferences.

Citi 2024 Global Healthcare Conference

On Wednesday, December 4, 2024, Owens & Minor is scheduled to participate in a fireside chat at 8:45 a.m. ET and host individual investor meetings at the conference in Miami, Florida.

Bank of America Home Care Conference

On Monday, December 9, 2024, Owens & Minor is scheduled to participate in a fireside chat at 12:00 p.m. ET and host individual investor meetings at the virtual conference.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

Assertio

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page